Accès ouvert
2025
article
OpenAlex
Akshay S. Desai, Adam D. Karns, Jolita Badarienė, Ahmad Aswad et autres
Importance: In prior monotherapy studies of patients with hypertension, single subcutaneous doses of zilebesiran, an investigational RNA interference therapeutic, reduced serum angiotensinogen levels and systolic blood pressure (SBP) at 3 and 6 months. Objective: To evaluate the efficacy and safety of zilebesiran …
us, lt, gb
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
George L. Bakris, Manish Saxena, Anil Gupta, Fadi M. Chalhoub et autres
Importance: Angiotensinogen is the most upstream precursor of the renin-angiotensin-aldosterone system, a key pathway in blood pressure (BP) regulation. Zilebesiran, an investigational RNA interference therapeutic, targets hepatic angiotensinogen synthesis. Objective: To evaluate antihypertensive efficacy and safety of different zilebesiran dosing regimens. Design, …
us, gb
(code pays fourni par la source)
2020
article
OpenAlex
Ilapreet Toor, Phoebe D. Edwards, Nagham Kaka, Rebecca Whitney et autres
ca
(code pays fourni par la source)